Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Truvada and Baricitinib for COVID-19 (PanCOVID)
NCT04890626Phase 3Completed
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of emtricitabine + tenofovir disoproxil, baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Hospital La Paz Institute for Health Research. Started Apr 2020; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxilbaricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04890626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890626.